[Treatment of transplant-eligible symptomatic multiple myeloma]

Rinsho Ketsueki. 2014 Oct;55(10):2016-26.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Autografts
  • Bendamustine Hydrochloride
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Combined Modality Therapy
  • Consolidation Chemotherapy
  • Cyclophosphamide / administration & dosage
  • Dexamethasone / administration & dosage
  • Drug Discovery
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Induction Chemotherapy
  • Lenalidomide
  • Maintenance Chemotherapy
  • Melphalan / administration & dosage
  • Multiple Myeloma / therapy*
  • Neoplasm, Residual
  • Nitrogen Mustard Compounds / administration & dosage
  • Pyrazines / administration & dosage
  • Remission Induction
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives
  • Transplantation Conditioning

Substances

  • Boronic Acids
  • Nitrogen Mustard Compounds
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • Cyclophosphamide
  • Bendamustine Hydrochloride
  • Lenalidomide
  • Melphalan